Rapid Micro Biosystems (RPID) opened Q1 2026 with revenue of US$8.0 million and a basic EPS loss of US$0.31, while trailing twelve month revenue stood at US$34.4 million alongside a TTM basic EPS loss of US$1.11. Over recent quarters the company has seen revenue move between US$7.2 million and US$11.3 million, with quarterly basic EPS losses ranging from US$0.22 to US$0.31. This latest print keeps the focus squarely on how fast margins can tighten and losses can narrow from here.

See our full analysis for Rapid Micro Biosystems.

With the headline numbers on the table, the next step is to set these results against the widely followed narratives about Rapid Micro Biosystems to see which stories still hold up and which need updating.

LTM loss of US$50.1 million sets the hurdle

• On a trailing twelve month basis, Rapid Micro Biosystems reported revenue of US$34.4 million against a net loss of US$50.1 million, with basic EPS over that period at a loss of US$1.11.
• Analysts' consensus view points to higher revenue but ongoing losses, and this quarter underlines that tension:
  • Consensus expects revenue growth of about 16.2% per year. However, the latest LTM figures still pair US$34.4 million of revenue with US$50.1 million of losses, which keeps profitability concerns front and center.
  • The consensus narrative highlights recurring consumables and service revenue as a support for margins. At the same time, the current loss level suggests that fixed costs and spending still sit well above what the existing revenue base can carry.

Price-to-sales at 3.2x with an US$8.00 target

• With a current share price of US$2.32 and a P/S of 3.2x, the stock is priced slightly below the US Life Sciences industry average P/S of 3.4x but above the peer average of 2.1x, while the analyst price target sits at US$8.00.
• Consensus narrative leans on revenue growth and improving margins to support that target, and the current numbers give mixed signals:
  • To line up with the US$8.00 target, the narrative assumes revenue of US$48.8 million and earnings of US$6.9 million by 2028, a sharp contrast to the current LTM loss of US$50.1 million.
  • The company has reportedly been shrinking losses at about 8.2% per year over five years, which is cited as evidence of progress. However, the gap from today's loss level to the earnings implied in that target remains wide.

Cash runway under one year raises risk

• The company is assessed as having less than one year of cash runway, at the same time as LTM net losses stand at US$50.1 million and shares have been more volatile than the broader US market over the past three months.
• Bears focus on liquidity and balance sheet pressure, and the current data gives them several concrete anchors:
  • The short cash runway, combined with ongoing losses and recent insider selling over the last three months, supports the cautious view that further funding or tighter cost control may be needed.
  • Concerns about increased debt and the US$45 million term loan in the bearish narrative line up with the reality of continued losses, which can limit flexibility if performance milestones on that financing are not met.

On top of these pressures, skeptics argue that volatility, insider selling, and the thin cash buffer make execution risk much higher than the headline revenue story suggests. As a result, it is worth reading the full bear and bull arguments side by side before deciding where you stand. 📊 Read the what the Community is saying about Rapid Micro Biosystems.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Rapid Micro Biosystems on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of pressure points and potential rewards in these results, it makes sense to review the data yourself and decide where you stand. To weigh both sides quickly, start with the 1 key reward and 4 important warning signs.

See What Else Is Out There

Rapid Micro Biosystems pairs an LTM net loss of US$50.1 million with less than one year of cash runway and recent insider selling, which concentrates risk.

If you want ideas where balance sheets and risk profiles look sturdier, today is a good time to check out the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.